Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats

Biotransformation and transplacental transfer of the anti-viral remdesivir and predominant metabolite, GS-441524 in pregnant rats

Summary: Background: Remdesivir was the first prodrug approved to treat coronavirus disease 2019 (COVID-19) and has the potential to be used during pregnancy. However, it is not known whether remdesivir and its main metabolite, GS-441524 have the potential to cross the blood-placental barrier. We h...

Full description

Bibliographic Details
Main Authors:	Ling Yang, I-Hsin Lin, Lie-Chwen Lin, Jeffrey W. Dalley, Tung-Hu Tsai
Format:	Article
Language:	English
Published:	Elsevier 2022-07-01
Series:	EBioMedicine
Subjects:	Remdesivir GS-441524 Microdialysis Blood-placental barrier Pharmacokinetics
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352396422002766

Similar Items

Transplacental transfer of Remdesivir and GS‐441524: An ex vivo perfusion study
by: Margaux Louchet, et al.
Published: (2023-07-01)

Assessing in vitro stability of remdesivir (GS-5734) and conversion to GS-441524 in feline plasma and whole blood
by: Sally J. Coggins, et al.
Published: (2024-12-01)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
by: Shiho Chiba, et al.
Published: (2022-02-01)

Quantification of GS-441524 concentration in feline plasma using high performance liquid chromatography with fluorescence detection
by: Benjamin Kimble, et al.
Published: (2023-12-01)

Oral GS-441524 derivatives: Next-generation inhibitors of SARS‐CoV‐2 RNA‐dependent RNA polymerase
by: Zhonglei Wang, et al.
Published: (2022-12-01)

Nucleoside analog GS‐441524: pharmacokinetics in different species, safety, and potential effectiveness against Covid‐19
by: Henrik Berg Rasmussen, et al.
Published: (2022-04-01)

Uroliths composed of antiviral compound GS‐441524 in 2 cats undergoing treatment for feline infectious peritonitis
by: Marissa Allinder, et al.
Published: (2024-01-01)

Unlicensed GS-441524-Like Antiviral Therapy Can Be Effective for at-Home Treatment of Feline Infectious Peritonitis
by: Sarah Jones, et al.
Published: (2021-07-01)

Comparative Evaluation of GS-441524, Teriflunomide, Ruxolitinib, Molnupiravir, Ritonavir, and Nirmatrelvir for In Vitro Antiviral Activity against Feline Infectious Peritonitis Virus
by: Subarna Barua, et al.
Published: (2023-08-01)

Preclinical Pharmacokinetics and In Vitro Properties of GS-441524, a Potential Oral Drug Candidate for COVID-19 Treatment
by: Amy Q. Wang, et al.
Published: (2022-08-01)

Potential therapeutic effects of GS-441524 and GC376 in cats with feline infectious peritonitis
by: Omid Nekouei, et al.
Published: (2022-02-01)

Cellular Uptake and Intracellular Phosphorylation of GS-441524: Implications for Its Effectiveness against COVID-19
by: Henrik Berg Rasmussen, et al.
Published: (2021-07-01)

Effect of GS-441524 in combination with the 3C-like protease inhibitor GC376 on the treatment of naturally transmitted feline infectious peritonitis
by: Jinbao Lv, et al.
Published: (2022-10-01)

Combination of the parent analogue of remdesivir (GS-441524) and molnupiravir results in a markedly potent antiviral effect in SARS-CoV-2 infected Syrian hamsters
by: Rana Abdelnabi, et al.
Published: (2022-12-01)

Comparison of anti-SARS-CoV-2 activity and intracellular metabolism of remdesivir and its parent nucleoside
by: Sijia Tao, et al.
Published: (2021-01-01)

Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro
by: Linda Brunotte, et al.
Published: (2021-09-01)

Peritonite infecciosa felina: Revisão
by: Isabela Lopes Massitel, et al.
Published: (2021-01-01)

Transplacental transfer of acetaminophen in pregnant rats
by: Jung-Hung Chen, et al.
Published: (2022-10-01)

Coronavirus Infection of the Central Nervous System: Animal Models in the Time of COVID-19
by: Peter J. Dickinson
Published: (2020-10-01)

Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
by: Wei Ye, et al.
Published: (2020-06-01)

Corrigendum: Remdesivir (GS-5734) Impedes Enterovirus Replication Through Viral RNA Synthesis Inhibition
by: Wei Ye, et al.
Published: (2020-11-01)

Differential cytokine responses in hospitalized COVID-19 patients limit efficacy of Remdesivir
by: Chan, Yi-Hao, et al.
Published: (2022)

Assessment of Purity, Stability, and Pharmacokinetics of NGP-1, a Novel Prodrug of GS441254 with Potential Anti-SARS-CoV-2 Activity, Using Liquid Chromatography
by: Chen Sun, et al.
Published: (2023-07-01)

Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma
by: Christine Skaggs, et al.
Published: (2022-08-01)

Remdesivir, compuesto con potencial terapéutico contra SARS-CoV-2
by: Anthony Paul Bautista-Pariona, et al.
Published: (2021-02-01)

Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: A retrospective cohort study
by: Yazed Saleh Alsowaida, et al.
Published: (2023-02-01)

Remdesivir and the Liver: A Concise Narrative Review of Remdesivir-Associated Hepatotoxicity in Patients Hospitalized Due to COVID-19
by: Alireza FakhriRavari, et al.
Published: (2024-02-01)

Remdesivir—Bringing Hope for COVID-19 Treatment
by: Naser F. Al-Tannak, et al.
Published: (2020-06-01)

Remdesivir Inhibits Tubulointerstitial Fibrosis in Obstructed Kidneys
by: Lin Xu, et al.
Published: (2021-07-01)

Evidence for the Effectiveness of Remdesivir (GS-5734), a Nucleoside-Analog Antiviral Drug in the Inhibition of IK(M) or IK(DR) and in the Stimulation of IMEP
by: Wei-Ting Chang, et al.
Published: (2020-07-01)

Differential Cytokine Responses in Hospitalized COVID-19 Patients Limit Efficacy of Remdesivir
by: Yi-Hao Chan, et al.
Published: (2021-06-01)

Available Evidence and Ongoing Clinical Trials of Remdesivir: Could It Be a Promising Therapeutic Option for COVID-19?
by: Mekonnen Sisay
Published: (2020-05-01)

Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
by: E. Susan Amirian, et al.
Published: (2020-06-01)

Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis
by: Vikas Bansal, et al.
Published: (2021-01-01)

Mechanism of Inhibition of Ebola Virus RNA-Dependent RNA Polymerase by Remdesivir
by: Egor P. Tchesnokov, et al.
Published: (2019-04-01)

ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential
by: Subrata Deb, et al.
Published: (2021-07-01)

An Optimized Bioassay for Screening Combined Anticoronaviral Compounds for Efficacy against Feline Infectious Peritonitis Virus with Pharmacokinetic Analyses of GS-441524, Remdesivir, and Molnupiravir in Cats
by: Sarah Cook, et al.
Published: (2022-11-01)

Jubilee G.S. Yunusov – 75 years!
by: article Editorial
Published: (2019-02-01)

Extracorporeal membrane oxygenation may decrease the plasma concentration of remdesivir in a patient with severe coronavirus disease 2019
by: Satoshi Ide, et al.
Published: (2021-01-01)

Stopping Feline Coronavirus Shedding Prevented Feline Infectious Peritonitis
by: Diane D. Addie, et al.
Published: (2023-03-01)